INTRODUCTION
There is increasing evidence that Ca2+ controls the activity of the contractile machinery of smooth muscle by modulating proteins associated with both the myosincontaining thick filaments and the actin-based thin filaments (summarized by Marston, 1983) . Evidence for myosin regulation, by means of a Ca2+-dependent phosphorylationmechanism,iswellestablished (Sobieszek & Small, 1977; Adelstein, 1978; Hartshorne & Siemankowski, 1981) . In contrast, there has been disagreement on the existence and nature of a thin-filament-linked Ca2+-regulatory system. Reasons for the latter controversy involved both the lack of a common approach and the use of different smooth muscle tissues by various investigators.
Initial studies by Sobieszek & Small (1976) showed that visceral smooth-muscle thin filaments consist only of actin and tropomyosin, indicating a complete lack of possible Ca2+-dependent regulatory proteins associated with such thin filaments. This conclusion now appears to be tenuous, since we have found that the proteins interacting with smooth-muscle thin filaments, including the tropomyosin component, are labile and tend to dissociate in standard thin-filament extraction buffers . In fact, several groups have suggested the presence of thin-filament-based regulatory proteins in smooth muscle (Driska & Hartshorne, 1975; Ebashi et al., 1977; Marston et al., 1980; . Moreover, one of us (S. B. M.) has isolated Ca2+-regulated thin filaments from vascular smooth muscle which confer Ca2+-dependence on Ca2+-insensitive myosin (Marston et al., 1980; . Disassembly and reconstitution studies on this system have shown that regulation is achieved via a 120000A140000-Mr protein, possibly caldesmon, which inhibits actin-tropomyosin, plus a Ca2+-binding protein, similar to calmodulin, which reverses the inhibition when Ca2+ is bound Smith & Marston, 1985) . In the present study, we demonstrate that the 120000140000-Mr protein is caldesmon and is responsible for the observed Ca2+-sensitivity ofall smooth-muscle thin filaments.
Caldesmon, first identified by Kakiuchi and associates, is a major calmodulin-binding protein found in a variety of smooth muscle tissues in appreciable quantity (Sobue et al., 1982; Ngai et al., 1984; Bretscher, 1984) . Experimentation in vitro, using purified proteins, shows caldesmon to have a high affinity for actin in the absence of calmodulin and Ca2+. These studies have also shown that caldesmon binding to actin can both inhibit actomyosin ATPase and cause lateral cross-linking of actin filaments. To date, however, the identification of caldesmon as a putative actin-linked regulatory protein is based almost entirely on binding studies in vitro using purified proteins. Such methods have shown that many non-contractile proteins can associate with actin (Clark et al., 1983; Stewart et al., 1983) , an effect having unknown physiological significance. It is possible that caldesmon may spuriously bind to purified actin and likewise may be a contaminant in native smooth muscle thin filament preparations. This, however, does not seem to be the case, and evidence is presented here showing that caldesmon is a component of the smooth-muscle thin filament in vivo.
MATERIALS AND METHODS
Aorta tropomyosin, F-actin and skeletal-muscle myosin were prepared as described by . Thiophosphorylated aorta myosin was prepared as described by Chacko & Rosenfeld (1982) and Heaslip & Chacko (1985) . Smooth-muscle thin filaments from a variety of tissues were isolated as described by Marston , and 120000-140000-Mr protein was purified directly from such preparations by the method of Smith & Marston (1985) .
A new method was developed for isolating chicken gizzard thin filaments of high purity. The salient features of the technique involve precise pH measurement and adjustment (to eliminate myosin contamination) and thin-filament extraction in the presence of ATP and EGTA at 25 'C. This prevents tropomyosin dissociation, which otherwise occurs at 4 'C. The pH of all buffers was adjusted at 25 'C, and they were used at either 25 'C or 4 'C as indicated. In the 4 'C steps, gizzard snooth-muscle tissue was homogenized (40 s each time, in a Sorvall Omni-Mixer), and washed by sedimentation (18 000 g for 5 min) in a buffer consisting of 100 mM-NaCl, 10 mMsodium phosphate (pH 7.0), 5 mM-MgC12, 1 mM-EGTA, 1 mM-NaN3 and 1 mM-dithioerythritol (Sol. A). This process was repeated four times; the first two washes contained additional 1 % Triton X-100. In the 25 'C steps, the resultant white pellets ('washed muscle') were rehomogenized in Sol. A, then 100 mM-ATP (pH 7.0) was added (final concn. 5 mm), and the suspension sedimented (12000 g for 5 min). The pellets were then resuspended by gentle stirring in fresh Sol. A+ 5 mM-ATP and resedimented. These pellets were subsequently homogenized in Sol. A + 5 mM-ATP, and particulate material was removed by centrifugation at 120000 g for 10 min. Thin filaments were collected by centrifugation at 120000 g for 150 min. They were resuspended in Sol. A adjusted to pH 6.0, and ATP was added (final concn. 5 mM). The pH ofthe suspension was decreased to pH 5.75 with 1 M-HCl, and contaminating myosin removed by centrifugation at 40000 g for 10 min. (Wang et al., 1975). dialysed overnight (at 4°C) against Sol. A adjusted to pH 6.25, and precipitated material removed by centrifugation at 120000 g for 10 min. Pure thin filaments were c IleSted by centrifugation at 120000 g for 150 min (at 25°C) and resuspended in Sol. A. Before use, small amounts of aggregated material were removed by centrifugation at 40000 g for 10 min. This method was used ten times without variation in the purity of the thin filaments obtained (Figs. 2a and 2b) . The yield was 6-8 mg/g wet wt. of tissue. Caldesmon was prepared by several procedures. Chicken gizzard caldesmon, prepared as described by Ngai et al. (1984) , was given by Dr. Clive Sanders (University of Alberta); chicken gizzard caldesmon, prepared as described by Sobue et al. (1981) , was given by Dr. Renata Dabrowska (Nencki Institute, Warsaw, Poland). Sheep aorta caldesmon was prepared by a modification ofBretscher's (1984) method. A heat-treated extract of homogenized aorta was obtained as described by Bretscher (1984) , and caldesmon was purified from the extract by isoelectric fractionation at pH 3.0 (where caldesmon alone is soluble) and (NH4)2S04 fractionation (40-50% satn.) as described by Smith & Marston (1985) .
Gizzard caldesmon used for antibody production (Fig.  2c) Ngai et al. (1984) or Bretscher (1984) . The protein was purified further by preparative alkaline 6 M-urea/polyacrylamide-gel electrophoresis and used to immunize rabbits as described by Lehman et al. (1980) . Antibodies to chicken gizzard myosin light-chain kinase were given by Dr. J. F. Head and Dr. B. Kaminer (Boston University). IgG fractions were prepared as described by Lehman et al. (1980) .
ATPase assay was performed as described by , and SDS/polyacrylamide-gel electrophoresis as described by either or Weber & Osborn (1969) as indicated. Western immunoblotting to determine antibody specificity was performed by the method of Towbin et al. (1979) . Non-competitive enzyme-linked immunoabosrbent assay was carried out (Tsang et al., 1983 ) with horseradish-peroxidaseconjugated anti-rabbit IgC (Miles-Yeda), H202 as substrate, and a hydrogen donor chromogen, ophenylenediamine. The reaction was stopped after 3 min with 0.75 M-H2SO4 and A492 was read as described by Engvall (1980) .
RESULTS
Using the method of , we obtained native thin filaments from chicken gizzard, rabbit stomach, sheep trachea and sheep aorta (Fig. 1) . A new method has also been developed for preparing chicken gizzard thin filaments which produces a product with negligible myosin contamination (Figs. 2a and 2b) . All the thin-filament preparations contained three major components: actin, tropomyosin and a 120000-140000-Mr protein, and also minor amounts of filamin . The 120 000-140 000-Mr protein migrated with different Mr values on different SDS/polyacrylamide-gel systems: method, 120000; Weber & Osborn (1969) method, 135000; Laemmli (1970) Assay was described by Smith & Marston (1985) . Conditions were as follows: 0.5 mg of aorta actin/ml, 0.15 mg of aorta tropomyosin/ml, 0.125 mg of skeletal myosin/ml (25°C), 5 mM-Pipes, pH 7.1, 60 mM-KCl, 5 mM-MgCl2, 5 mM-NaN3, 1 mM-dithiothreitol, 2 mmMgATP. Pi released in 10 min was assayed.
the same in each preparation (Fig. 1, Table 1 ). Trachea thin filaments were obtained in low yield and contained significant impurities: this may reflect a low muscle content of whole trachea. Some prepartions [method of ] were tested for activation of thiophosphorylated aorta myosin MgATPase: at 37°C they all activated aorta myosin by 10-30-fold in the presence of 10 uM-Ca2+, but activated less than 3-fold in the absence of Ca2+ (Table 1) . This Ca2+-sensitivity is considerably better than for the same preparations tested with skeletal myosin . In contrast, actin-tropomyosin activated with little or no Ca2+-sensitivity under these ionic conditions (Table 1) , confirming the results of Chacko & Rosenfeld (1982) . Thus Ca2+-regulated thin filaments of a similar composition can be obtained independent of source. In addition, the 120000-140000-Mr protein was isolated directly from thin filaments in relatively high yield (0.015-0.020 mg/mg of thin filament in each case). All the 120000-140000-Mr protein preparations were equally potent inhibitors of the activation of myosin ATPase by actin-tropomyosin (Fig. 3) .
We compared the electrophoretic mobility of the 120000-140000-Mr protein isolated directly from thin filaments with purified gizzard and aorta caldesmon and found them to be indistinguishable on SDS/4-30% -polyacrylamide-gradient-gel electrophoresis. Fig. 4 shows the result for the aorta proteins. Additionally, 120000-140000-Mr protein isolated from aorta and gizzard thin filaments and purified aorta and gizzard caldesmon were compared by the peptide-mapping procedure of Cleveland et al. (1977) . The Sa) , as are the 120000-140000-Mr aorta thin-filament component and purified aorta caldesmon (Fig. Sb) . Except for minor differences, the peptide maps of the gizzard and aorta proteins closely resemble each other (Fig. 5a ). Further confirmation that the 120000-140000-Mr protein is caldesmon is evident from the observation that some of the protein characteristically dissociates from chicken gizzard and aorta native thin filaments in the presence of Ca2+ and added calmodulin, consistent with the results of Sobue et al. (1982) , Ngai et al. (1984) and Smith & Marston (1985) . As mentioned, a new method was developed for the preparation of very pure gizzard thin filaments for use in the immunological studies described below. These thin filaments retain a full complement of tropomyosin and are free of myosin contamination (Fig. 2) . Antibodies were developed against purified chicken gizzard caldesmon, and immunoblotting shows that they react with the 120000-140000-Mr caldesmon band on chicken gizzard thin filaments and with no other protein in chicken gizzard muscle (Fig. 2) . The antibody reacts with the 120000-Mr band of aorta thin filaments, but not as strongly as with gizzard. Immunoprecipitation studies show that anti-caldesmon antibody not only interacts with caldesmon antigen but precipitates intact thin filaments as well. In fact, at saturating concentrations, the antibody precipitates over 80O% of the actin in chicken gizzard thin-filament preparations (Fig. 6 ). This result indicates that caldesmon is a component bound to thin filaments and not simply a contaminant co-purifying with thin-filament preparations. Furthermore, the antibody was used in quantitative enzyme-linked immunoabsorbent assay, showing that the caldesmon concentration present in gizzard thin-filament preparations is 2.1 times that in unfractionated washed muscle (Fig. 7) . Since the actin concentration in such thin-filament preparations is also approximately twice (2.2 times) that in unfractionated muscle, these results suggest that caldesmon must be an actin-bound component in vivo which is retained during isolation.
Enzyme-linked immunoabsorbent assay using anti-(myosin light-chain kinase) antibody demonstrates that myosin light-chain kinase is not a constituent of our native thin filaments (Fig. 7) . Also, our elution profile of thin-filament extracts separated on a DEAE-Sephacel column (performed as described by Ngai et al., 1984) indicates that the myosin light-chain kinase content of thin filaments is at most 2% that of caldesmon.
DISCUSSION
Using our new preparative procedures, we have demonstrated that thin filaments of similar composition can be extracted from any smooth muscle. Activation of smooth-muscle myosin MgATPase by these thin filaments is highly Ca2+-dependent. SDS/polyacrylamide-gel electrophoresis shows they all consist of actin, tropomyosin, a single 120000-140000-Mr protein, and small amounts of filamin (a cytoskeletal protein) (Fig. 1, Table 1 ). The thin-filament preparations all contain comparable amounts of the 120000-140000-Mr protein, which when isolated is a potent inhibitor of actomyosin ATPase (Fig.   3 ) and, as previously shown, is a necessary component of the thin-filament-linked Ca2+-regulatory system in vascular smooth muscle Smith & Marston, 1985) . This protein has many properties in common with Kakiuchi's caldesmon preparation (Sobue Gel pieces containing 10 ug ofpure protein (Fig. 4) were cut out and placed on a 20 % -polyacrylamide/ 1 % -SDS gel with a 2 cm-wide 4% -polyacrylamide stacking gel (Laemmli, 1970) , together with an equal quantity (w/w) of Staphylococcus aureus V8 protease.
Gels were run into stacking gel for 1.25 h at 100 V, followed by a wait of 30 min, followed by electrophoresis at 300 V in separating gel (Cleveland et al., 1977) . Temperature was maintained at 17 'C. In Fig. 5(a (Fig. 1) (Ebashi et al., 1977; Ebashi, 1980) . Our studies also indicated that myosin light-chain kinase is not a component of native smooth-muscle thin filaments (Fig. 7) , confirming previous results , even though it has been shown capable of binding to actin (Sellers & Pato, 1984) .
Anti-caldesmon IgG (mg)
Immunoprecipitation assays show that caldesmon is filaments, indicating that it must be part of the contractile In this experiment, various amounts of IgG prepared from machinery (Fig. 6) . Moreover, enzyme-linked immunoanti-caldesmon serum (w) or from non-immune control absorbent assay implies that caldesmon cannot be a serum (0) were mixed with 1 mg of clarified thin filaments, contaminant of thin-filament preparations and must be themixtureswere adjusted to 1 mlwith phosphate-buffered a component of the thin filament in vivo, since there are saline (PBS; 150 mM-NaCl/10 mM-sodium phosphate equal caldesmon/actin ratios in unfractionated tissue and buffer, pH 7.0), and allowed to react at 25°C for 1 h; these in isolated thin filaments (Fig. 7 ).
samples were then centrifuged for 10 min at 9000 rev./min. Smith & Marston, 1985) or by Ca2+-calmodulin anti-caldesmon antibody more than 80% of the actin of activating a caldesmon kinase (Ngai & Walsh, 1985) . It thin filaments is precipitated. The experiment was is also not clear whether the influence of caldesmon on performed on two preparations of thin filaments, and the actomyosin ATPase and its effect on actin-filament results were also confirmed, qualitatively, by observing a cross-linking are distinct functions (Bretscher, 1984;  complete loss of thin-filament birefringence after anti- ...., ----) suspended in 0.6 M-NaCl/40 mmNa2CO3/NaHCO3 buffer (pH 9.6), was resuspended in 40 mM-Na2CO3/NaHCO3 buffer (pH 9.6) and used, in concentrations specified on the abscissa, to sensitize polystyrene tubes. The coated tubes were incubated with anti-caldesmon serum (0, 0), anti-(myosin light-chain kinase) serum regulating shortening velocity or tension in contracting muscle, or in effecting stress maintenance during relaxation (i.e. the 'latch' state; Aksoy et al., 1981) . In addition to being found in smooth muscle, caldesmon has also been identified in non-muscle cells Owada et al., 1984; Ngai & Walsh, 1985) . Hence the caldesmon-based Ca2+-dependent regulatory system may be a general mechanism for controlling smoothmuscle and cellular actin-myosin interactions.
